An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease

Vaccines, Journal Year: 2025, Volume and Issue: 13(1), P. 52 - 52

Published: Jan. 9, 2025

Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and fusion (F) protein is a target for neutralizing antibodies vaccine development. This study aimed to investigate immunogenicity efficacy an mRNA-based RSV with F sequence. We designed mRNA construct encoding modified protein, which was further developed into LNP-encapsulated (LVRNA007). LVRNA007 administered mice cotton rats, followed by analysis viral challenge studies. Protection rodents from evaluated based on presence in lung pathological examination tissues. induced robust humoral cellular immune responses both neutralization antibody levels immunized animals maintained at high over one year. Vaccination also protected challenge, judged much decreased titer score tissue. In addition, no vaccine-enhanced disease (VED) phenomenon observed vaccination. Based preclinical data, could be potential promising prophylaxis infection.

Language: Английский

---

Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 335 - 335

Published: March 21, 2025

Combination vaccines provide the versatile benefits of addressing different pathogens simultaneously using a combined formulation. This approach can be regarded as substantial modernization in immunization. In this review, we highlight various advancements combination based on mRNA, viral vectors, live attenuated, and recombinant vaccines. Recent success clinical trials mRNA platforms for has particularly accelerated research direction. The advantages terms patient adherence, cost effectiveness, streamlined immunization schedule are discussed. existing challenges antigenic interference, logistical hurdles, complications regulatory standards analyzed. Research trends to make viable emerging infections have been summarized. current work provides critical overview, opportunities, future prospects

Language: Английский

---

The Bright Future of mRNA as a Therapeutic Molecule

Genes, Journal Year: 2025, Volume and Issue: 16(4), P. 376 - 376

Published: March 26, 2025

The rapid success of messenger (m) RNA vaccines against COVID-19 has pushed the mRNA to forefront drug research. promise mRNA-based therapeutics and in other areas is not new but now emerging stronger. We review basic concepts, key historical aspects, recent research on as a therapeutic molecule fight infectious diseases cancer. also show current patent perspective this field. Altogether, we describe that technology rapidly moving field aiming for bright future.

Language: Английский

---

Cytokine Storms and Anaphylaxis Following COVID-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches

Diseases, Journal Year: 2024, Volume and Issue: 12(10), P. 231 - 231

Published: Oct. 1, 2024

Acute adverse reactions to COVID-19 mRNA vaccines are a major concern, as autopsy reports indicate that deaths most commonly occur on the same day of or one following vaccination. These acute may be due cytokine storms triggered by lipid nanoparticles (LNPs) and anaphylaxis induced polyethene glycol (PEG), both which vital constituents mRNA-LNP vaccines. Kounis syndrome, in triggers coronary syndrome (ACS), also responsible for these cardiovascular events. Furthermore, encompass adjuvants, such LNPs, trigger inflammatory cytokines, including interleukin (IL)-1β IL-6. produce spike proteins facilitate release cytokines. Apart from this, histamine released mast cells during allergic plays critical role IL-6 secretion, intensifies responses. In light events, early reduction IL-1β is imperative managing post-vaccine storms, ACS, myocarditis. Corticosteroids can restrict cytokines mitigate responses, while colchicine, known its IL-1β-reducing capabilities, could prove effective. The anti-IL-6 antibody tocilizumab displays promising treatment syndrome. Aside significance treating anaphylaxis, epinephrine induce artery spasms myocardial ischemia making accurate diagnosis essential. upcoming self-amplifying contain LNPs. Given cause storm post vaccination, it crucial consider corticosteroids measure levels effective management.

Language: Английский

---

COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2

International Journal of Vaccine Theory Practice and Research, Journal Year: 2024, Volume and Issue: 3(2), P. 1275 - 1344

Published: Aug. 16, 2024

The COVID-19 modified mRNA (modmRNA) lipid nanoparticle-based “vaccines” are not classical antigen-based vaccines but instead prodrugs informed by gene therapy technology. Of considerable note, these products have been linked to atypical adverse and serious event profiles. As discussed in Part 1, health-related risks drawbacks were drastically misreported underreported the Pfizer Moderna trial evaluations of genetic products. Now 2, we examine main structural functional aspects injectables. modmRNA injectable introduce a unique set biological challenges human body with potential induce an extensive range adverse, crippling, life-threatening effects. Based on fact that there is no current method quantify host (cell-based) spike protein production vivo following injection prodrugs, standard “dose”. This part due differences output, which depends cell metabolism transfection efficiency. It therefore difficult predict profiles individual basis, considering millions adults across world reported severe events context products, valid concerns raised regarding infants younger age groups for whom poses only minimal risks. We address process-related impurities inherent mass posed contaminants. then categorize principal associated brief systems-based synopsis each six domains harms: (1) cardiovascular, (2) neurological, (3) hematologic; (4) immunological, (5) oncological, (6) reproductive. conclude discussion primary public health regulatory issues arising from this evidence-informed synthesis literature reiterate urgency imposing global moratorium modmRNA-LNP-based platform.

Language: Английский

---

Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy

Published: May 30, 2024

The rapid development and authorization of mRNA vaccines by Pfizer-BioNTech (BNT162b2) Moderna (mRNA-1273) in 2020 marked a significant milestone human product application, overcoming previous obstacles such as instability immunogenicity. This paper reviews the strategic modifications incorporated into these to enhance stability translation efficiency, inclusion nucleoside optimized design elements including 5’ cap poly(A) tail. We highlight emerging concerns regarding wide systemic biodistribution leading prolonged inflammatory responses other safety concerns. regulatory framework guiding studies is pivotal assessing profiles new formulations use today. vaccines, their pervasive distribution, longevity encapsulated along with unlimited production damaging potentially lethal Spike (S) protein call for strategies mitigate potential adverse effects. Here, we explore small interfering RNA (siRNA) ribonuclease targeting chimeras (RIBOTACs) promising solutions target, inactivate, degrade residual persistent vaccine mRNA, thereby preventing uncontrolled reducing toxicity. targeted nature siRNA RIBOTACs allows precise intervention, offering path prevent events mRNA-based therapies. review calls further research RIBOTAC applications antidotes detoxication products technology.

Language: Английский

---

Cancer Mortality Surges Post COVID ModRNA Vaccination Ronald Palacios Castrillo

European Journal of Clinical and Biomedical Sciences, Journal Year: 2024, Volume and Issue: 10(2), P. 23 - 27

Published: June 29, 2024

Recent investigations have revealed a concerning association between the administration of third dose ModRNA COVID-19 vaccine and statistically significant increases in cancer mortality rates. A study conducted Japan highlighted this correlation, noting marked rise cancer-related deaths post-vaccination. This phenomenon is not isolated to Japan; similar trends been observed Europe, Australia, USA, with an excess reported from 2020 2023 compared 2019. In review, we explore seven potential mechanisms through which vaccines may contribute initiation progression cancer. Each mechanism discussed detail, focus on underlying molecular cellular pathways. The for varied combinations these influence different types also considered, providing comprehensive overview how might impact biology. Our analysis underscores necessity further research elucidate precise relationship vaccination progression. Understanding critical developing strategies mitigate adverse effects while harnessing benefits vaccination.

Language: Английский

---

Strategic deactivation of mRNA COVID‐19 vaccines: New applications for siRNA therapy and RIBOTACs

The Journal of Gene Medicine, Journal Year: 2024, Volume and Issue: 26(9)

Published: Aug. 26, 2024

Abstract The rapid development and authorization of messenger ribonucleic acid (mRNA) vaccines by Pfizer‐BioNTech (BNT162b2) Moderna (mRNA‐1273) in 2020 marked a significant milestone human mRNA product application, overcoming previous obstacles such as instability immunogenicity. This paper reviews the strategic modifications incorporated into these to enhance stability translation efficiency, inclusion nucleoside optimized design elements including 5′ cap poly(A) tail. We highlight emerging concerns regarding wide systemic biodistribution leading prolonged inflammatory responses other safety concerns. regulatory framework guiding studies is pivotal assessing profiles new formulations use today. vaccines, their pervasive distribution, longevity encapsulated along with unlimited production damaging potentially lethal spike (S) protein call for strategies mitigate potential adverse effects. Here, we explore small interfering RNA (siRNA) ribonuclease targeting chimeras (RIBOTACs) promising solutions target, inactivate, degrade residual persistent vaccine mRNA, thereby preventing uncontrolled S reducing toxicity. targeted nature siRNA RIBOTACs allows precise intervention, offering path prevent events mRNA‐based therapies. review calls further research RIBOTAC applications antidotes detoxication products technology.

Language: Английский

---

mRNA Technologies Danger

Journal of NBC Protection Corps, Journal Year: 2024, Volume and Issue: 8(3), P. 205 - 231

Published: Nov. 19, 2024

Highlights. The impact that the technologies may exert on human genome is underestimated. mRNA represent a particular danger for genome. Relevance. are quite widespread in Western world. They also gaining popularity Russia and why we should control safety of such technologies. Purpose study – to determine potential hazard Study base sources full English academic periodicals available Internet. Method study. Analytical. author used suggestions Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA). Discussion. paper dwells essence scope technologies, discusses their way functioning, identifies shortcomings provoke pathological consequences humans; determines approaches permit use these genes. article proves nowadays imperfect, now it impossible predict near long-term they bring health. technology itself dual purpose can be under other names unleash biological war with new final goal population decline. newer agents influence will be, more dangerous become. methods application sophisticated. All this accompanied by media eliminate alternative opinions. This result decline general level knowledge about threats. Conclusion. We maintain rigid state over development any potentially ensure not names. It worth limiting them only oncology approximately 10 years. help identify range possible adverse application. injection drugs go from abroad checked nano objects "storage".

Language: Английский

---

A Case of Rapid Transformation of a Nail Matrix Nevi to Melanoma After Messenger RNA COVID-19 Vaccine: A Cause or a Coincidence?

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 24, 2024

Subungual melanoma is a variant of acral lentiginous that arises from the nail matrix. melanomas present unique clinical challenges due to diagnostic difficulties and lack standardized protocol for surveillance, also, there are no evidence-based studies determine ideal frequency duration dermoscopy follow-ups in patients with longitudinal melanonychia. This highlighted by case melanonychia 53-year-old patient who underwent malignant transformation subungual after biphasic growth. Another problem raised how long observe melanonychia, conclusion it should be observed lifetime. Finally, this report also illustrates possible role COVID-19 messenger RNA vaccine cancer development and/or progression.

Language: Английский

---